| Dr Chotinij Lertphanichkul, MD | |
|
850 Boylston St Ste 437, Chestnut Hill, MA 02467-2405 | |
| (617) 732-9090 | |
| (917) 232-1043 |
| Full Name | Dr Chotinij Lertphanichkul |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Location | 850 Boylston St Ste 437, Chestnut Hill, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831684224 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 274825 (Massachusetts) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Chotinij Lertphanichkul, MD 10 Emerson Pl Apt 3j, Boston, MA 02114-2218 Ph: (617) 320-8748 | Dr Chotinij Lertphanichkul, MD 850 Boylston St Ste 437, Chestnut Hill, MA 02467-2405 Ph: (617) 732-9090 |
News Archive
As many as 50 percent of all human protein-coding genes are regulated by microRNA (miRNA) molecules. While some miRNAs impact onset and progression of cancer, others can actually suppress the development of malignant tumors and are useful in cancer therapy. They can also serve as potential biomarkers for early cancer detection. In a new issue of Cancer Biomarkers, investigators report on non-coding miRNAs as appealing biomarkers for malignancy.
Lotus Pharmaceuticals, Inc., a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China, announced today that it has entered R-Bambuterol Clinical Trial I on-schedule and is on-track to complete in six months. The studies will evaluate the safety and tolerability of the new drug as well as the biological activity by measuring responses in healthy volunteers.
EpiCept Corporation has announced that it has filed a New Drug Submission (NDS) with Health Canada for Ceplene® (histamine dihydrochloride) for the treatment of acute myeloid leukemia (AML) patients in first complete remission. Health Canada typically accepts or refuses an NDS and designates review status within forty-five days of filing. If accepted, the customary timeframe for completion of review and an approval decision is within one year.
A novel strategy, new teams of researchers and increased funding are needed to revitalize the fight against HIV/AIDS worldwide, experts said Monday on the 25th anniversary of the release of the study that identified HIV, AFP/Google.com reports.
› Verified 8 days ago
Thomas Eugene Rohrer, M.D. Dermatology Medicare: May Accept Medicare Assignments Practice Location: 1244 Boylston St, Suite 302, Chestnut Hill, MA 02467 Phone: 617-731-1600 Fax: 617-731-1601 | |
Jeffrey Michael Sobell, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1244 Boylston St, Suite 302, Chestnut Hill, MA 02467 Phone: 617-731-1600 Fax: 617-731-1601 | |
Richard F Horan, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 850 Boylston St, Rhumatology Immunology And Allergy Suite 540, Chestnut Hill, MA 02467 Phone: 617-732-9850 | |
Prasanthi Kandula, Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1244 Boylston St, Chestnut Hill, MA 02467 Phone: 617-731-1600 | |
Kenneth Alfred Arndt, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1244 Boylston St, Suite 302, Chestnut Hill, MA 02467 Phone: 617-731-1600 Fax: 617-731-1601 | |
Jeffrey Steven Dover, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1244 Boylston St, Suite 302, Chestnut Hill, MA 02467 Phone: 617-731-1600 Fax: 617-731-1601 | |
Dr. Andrei Metelitsa, M.D., FRCPC Dermatology Medicare: Not Enrolled in Medicare Practice Location: 1244 Boylston St, Chestnut Hill, MA 02467 Phone: 617-731-1600 Fax: 617-731-1601 |